度妥昔珠单抗

度妥昔珠单抗INN:Duvortuxizumab[1])是一种嵌合/人源化单克隆抗体,设计用于治疗B细胞恶性肿瘤[2]该药物由杨森全球服务公司开发。[3]

度妥昔珠单抗
单克隆抗体
种类单链可变区片段英语Single-chain variable fragment
目标CD19
临床资料
ATC码
  • 未分配
识别信息
CAS号1831098-91-9
ChemSpider
  • none
UNII
KEGG
化学信息
化学式C4850H7485N1305O1487S35
摩尔质量108,989.98 g·mol−1

参考资料

  1. ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116 (PDF). WHO Drug Information. 2016, 30 (4) [2024-01-23]. (原始内容存档 (PDF)于2020-08-07). 
  2. ^ Izhak L, Cullen DE, Elgawly M, Luistro L, Johnson S, Bald J, Sasser AK, Balasubramanian S. Potent antitumor activity of duvortuxizumab, a CD19 x CD3 DART® molecule, in lymphoma models.. Cancer Research. July 2017. doi:10.1158/1538-7445.AM2017-3636. 
  3. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Duvortuxizumab页面存档备份,存于互联网档案馆), American Medical Association.